<DOC>
	<DOCNO>NCT01312818</DOCNO>
	<brief_summary>Both bortezomib vorinostat identify Phase II dose pediatric adult patient grade 4 dose limit toxicity observe prior study . The pre-clinical synergy 2 agent use combination along lack over-riding toxicity different mechanism action provide strong rationale clinical trial investigate bortezomib vorinostat combination . This trial use identify Phase II dose maximum tolerate dose agent acceptable toxicity profile prove feasible tolerable relapsed/refractory ALL population .</brief_summary>
	<brief_title>Bortezomib , Vorinostat Dexamethasone Relapsed/Refractory Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>This phase II study bortezomib 1.3 mg/m^2 intravenous pyelogram ( IVP ) day 1 , 4 , 8 , 11 , vorinostat 180 mg/m^2 mouth ( PO ) per day ( exceed 400 mg per day ) day 1-14 , dexamethasone 6 mg/m^2 PO day 4-15 treatment relapsed/refractory acute lymphoblastic leukemia ( ALL ) . No 3 treatment course may give .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis lymphoblastic lymphoma acute lymphoblastic leukemia ( ALL ) ≥ 5 % blast bone marrow ( M2/M3 ) without extramedullary disease meet one follow criterion : Refractory Disease/Induction Failure : Failure achieve initial remission 2 attempt standard induction therapy Relapsed Disease : Patients relapse # 1 high standard curative therapy therapy prolong survival exist . Patients Philadelphia chromosomepositive ( Ph + ALL ) eligible provide imatinib resistant intolerant . Patients CNS positive disease eligible . Age 2 30 year Karnofsky ≥ 50 % patient 16 year old Lansky status ≥ 50 patient 16 year age . Patients must life expectancy ≥ 8 week determine enrol investigator . Have acceptable organ function define within 7 day start treatment : Renal : creatinine clearance ≥ 70ml/min/1.73m^2 serum creatinine base age/gender follow : Maximum serum creatinine ( mg/dl ) 0.8 2 year &lt; 6 year ; 1.0 6 year &lt; 10 year ; 1.2 10 year &lt; 13 year ; 1.5 male 1.4 female 13 year &lt; 16 year ; 1.7 male 1.4 female ≥ 16 year Hepatic : ALT &lt; 5 x upper limit normal ( ULN ) total bilirubin ≤ 1.5x upper limit normal ( ULN ) age . Cardiac : leave ventricular ejection fraction ≥ 40 % echocardiogram/multi gated acquisition scan ( ECHO/MUGA ) . Normal QTc electrocardiogram ( EKG ) ( exceed upper limit normal men : 430 millisecond ( m ) ; woman : 450 m ; child 15 year : 440 m ) . Prior Therapy : Patients must recover nonhematologic toxic effect prior therapy entry onto trial . Recovery define Common Toxicity Criteria Adverse Events ( CTCAE ) version 4.0 toxicity grade &lt; 2 , unless otherwise specify Inclusion Exclusion Criteria . Cytotoxic therapy : Patients must last dose chemotherapy least two week prior study entry . Hematopoietic growth factor : At least 7 day since completion therapy growth factor least 14 day since pegfilgrastim ( Neulasta® ) administration . Biologic ( antineoplastic ) therapy : At least 7 day since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . Monoclonal antibody : At least 3 halflives antibody last administration monoclonal antibody . Hematopoietic Stem Cell Transplant ( HSCT ) : Patients experience relapse HSCT eligible , provide evidence GraftversusHost Disease ( GVHD ) . Women child bear potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment 2 month last dose chemotherapy . Sexually active men must agree use barrier contraceptive duration treatment 2 month last dose chemotherapy . Voluntary write consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject/guardian time without prejudice future medical care . Pregnant lactating . The agent use study know teratogenic fetus information excretion agent breast milk . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Pregnancy test require surgically sterilized woman . Known hypersensitivity bortezomib , boron mannitol agent ingredient use study . Inability swallow capsule . Grade 2 great peripheral neuropathy within 14 day study registration . Patients untreated positive blood culture progressive infection assess radiographic study . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( appendix VI ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Serious concomitant medical psychiatric disorder ( e.g. , active infection , uncontrolled diabetes ) , opinion investigator , would compromise safety patient likely interfere participation clinical study . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patient receive investigational drug within 14 day study registration . Radiation therapy within 3 week registration . Enrollment patient require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>